Structure Therapeutics Inc.
GPCR
$57.20
$3.456.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.57M | 14.80M | 15.74M | 13.44M | 13.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -100.00M | -- | -- | -- | -- |
| Total Operating Expenses | -13.74M | 73.79M | 70.45M | 56.31M | 47.06M |
| Operating Income | 13.74M | -73.79M | -70.45M | -56.31M | -47.06M |
| Income Before Tax | 33.17M | -65.60M | -61.52M | -46.74M | -36.34M |
| Income Tax Expenses | 170.00K | 108.00K | 139.00K | 98.00K | 136.00K |
| Earnings from Continuing Operations | 33.00M | -65.71M | -61.66M | -46.83M | -36.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.00M | -65.71M | -61.66M | -46.83M | -36.48M |
| EBIT | 13.74M | -73.79M | -70.45M | -56.31M | -47.06M |
| EBITDA | 14.47M | -73.41M | -70.16M | -56.04M | -46.80M |
| EPS Basic | 1.56 | -3.37 | -3.21 | -2.45 | -1.91 |
| Normalized Basic EPS | 0.35 | -0.70 | -0.67 | -0.51 | -0.26 |
| EPS Diluted | 1.56 | -3.37 | -3.21 | -2.45 | -1.91 |
| Normalized Diluted EPS | 0.35 | -0.70 | -0.67 | -0.51 | -0.26 |
| Average Basic Shares Outstanding | 63.39M | 58.49M | 57.55M | 57.35M | 57.30M |
| Average Diluted Shares Outstanding | 21.13M | 19.50M | 19.18M | 19.12M | 19.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |